期刊文献+

mad2检测作为小细胞肺癌早期诊断潜在指标的临床研究 被引量:1

The clinical research about early diagnosis of small cell lung cancer through mad2 detection
下载PDF
导出
摘要 目的:探讨有丝分裂阻滞缺陷蛋白基因2(mitotic arrest deficient 2,mad2)联合抗纺锤体抗体(anti-nuclear mitotic spindle apparatus antibody,MSA)和抗着丝点抗体(anti-centromere antibody,ACA)检测对诊断小细胞肺癌(small cell lung cancer,SCLC)的临床意义。方法:对120例SCLC、110例非小细胞肺癌(non-small cell lung cancer,NSCLC)患者和115例肺结节(pulmonary nodule,PN)患者用荧光定量PCR(qt-PCR)法检测mad2基因的表达,用间接免疫荧光法(indirect immunofluorescence assay,IFA)检测MSA,ACA的表达。结果:mad2基因在SCLC,NSCLC患者中均有表达;和NSCLC相比,mad2在SCLC中表达量更高(P<0.05);mad2诊断SCLC的ROC曲线下面积为0.799,诊断价值中等;相关性分析中MSA、ACA与SCLC的OR值分别为6.94和5.60;一致性分析中mad2基因联合MSA诊断的Kappa值为0.49;mad2联合ACA诊断的Kappa值0.42;并联分析诊断的敏感性为83.31%,特异性为79.34%,约登指数为0.62;串联分析诊断的敏感性为65.32%,特异性为93.35%,约登指数为0.59。结论:mad2在SCLC组中的表达量高于NSCLC组及肺结节组,在SCLC发生发展中起到重要作用;mad2检测联合MSA及ACA有助于提高诊断敏感性及特异性,对SCLC的早期检测、临床诊断及潜在的治疗方法有一定的应用价值。 Objective: To explore combined detection of mad2 with anti-nuclear mitotic spindle apparatus antibody (MSA) and anticentromere antibody (ACA) and their clinical value for the diagnosis of small cell lung cancer (SCLC). Methods: One hundred and twenty SCLC patients, 110 non-small cell lung cancer (NSCLC) patients, and 225 pulmonary nodule (PN) patients were enrolled in this study. The expression of mad2 was analyzed by qt-PCR. MSA and ACA were detected by indirect immunofluorescence (IIF) staining. Results: mad2 was overexpressed in SCLC and NSCLC samples (P〈0.05). There were significant differences between the results obtained for SCLC and NSCLC samples by qt-PCR (P〈0.05). AUC in ROC curve for mad2 expression was 0.799 with an intermediate diagnostic value. In the correlative analysis, the odds ratio of MSA and ACA was 6.94 and 5.60, respectively. In the correlation analysis, Kappa value of mad2 with MSA was 0.49, and Kappa value of mad2 with ACA was 0.42. In the parallel analysis, the sensitivity and specificity was 83.31% and 79.34%, respectively, while the Youden Index was 0.62. Moreover, in the serial analysis, the sensitivity and specificity was 65.32% and 93.35%, respectively, and the Youden Index was 0.59. Conclusions: In comparison with the NSCLC and PN samples, mad2 was overexpressed in SCLC samples. Therefore, mad2 ought to play a critical role in the pathology of SCLC. The combined expression of mad2 with MSA and ACA may contribute to enhancing the sensitivity and specificity of detection; this expression may allow early diagnosis and clinical diagnosis of SLCC and may be a promising treatment for SCLC.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2018年第2期67-71,共5页 Chinese Journal of Clinical Oncology
基金 国家自然科学基金项目(编号:81760382) 江西省科技计划项目(编号:2015BBG70154)资助
关键词 小细胞肺癌 MAD2 抗纺锤体抗体 抗着丝点抗体 small cell lung cancer (SCLC), mitotic arrest deficient 2 (mad2), anti-nuclear mitotic spindle apparatus antibody (MSA), anticentromere antibody (ACA)
  • 相关文献

参考文献3

二级参考文献14

  • 1李玲 ,张烜 ,李永哲 ,沈海丽 ,曾小峰 .抗着丝点抗体在干燥综合征中的临床意义[J].中华内科杂志,2004,43(10):778-779. 被引量:10
  • 2武永康,王兰兰,彭晓东,张瑞薇,孟宪栋.抗着丝点抗体在自身免疫性疾病中的临床应用价值探讨[J].华西医学,2005,20(4):650-652. 被引量:7
  • 3Tan EM. Antiunclear antibodies in scleroderma. Intern J Dermatol, 1981,20:569 - 573
  • 4Nakano M, Ohuchi Y, Hasegawa H et. al Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus. J Rheumatol 2000, 27 : 1403 - 1407
  • 5Yusuke Nakano,Toshiyuki Sumi,Masatomo Teramae,Masanari Morishita,Takeshi Fukuda,Hiroyuki Terada,Hiroyuki Yoshida,Yoshinari Matsumoto,Tomoyo Yasui,Osamu Ishiko.Expression of the mitotic-arrest deficiency 2 is associated with chemotherapyresistance in ovarian serous adenocarcinoma[J].Oncology Reports.2012(4)
  • 6A. Arivazhagan,Durairaj Kumar,Vinay Sagar,Irene Patric,S. Sridevi,Balaram Thota,Mallavarapu Srividya,K. Prasanna,K. Thennarasu,Neelima Mondal,A. Hegde,B. Chandramouli,V. Santosh,M. Rao,P. Kondaiah,K. Somasundaram.Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor[J].Journal of Neuro-Oncology.2012(2)
  • 7Tatsuya Kato,Yataro Daigo,Masato Aragaki,Keidai Ishikawa,Masaaki Sato,Satoshi Kondo,Mitsuhito Kaji.Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients[J].Lung Cancer.2011(1)
  • 8Caroline F Thorn,Teri E Klein,Russ B Altman.Pharmacogenomics and bioinformatics: PharmGKB[J].Pharmacogenomics.2010(4)
  • 9Gottfried E. Konecny,Giovanni Pauletti,Michael Untch,He-Jing Wang,Volker M?bus,Walther Kuhn,Christoph Thomssen,Nadia Harbeck,Ling Wang,Sophia Apple,Fritz J?nicke,Dennis J. Slamon.Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer[J].Breast Cancer Research and Treatment.2010(2)
  • 10Se Hoon Park,Junshik Hong,Young Saing Kim,Yujin Kim,Sun Young Kyung,Chang Hyeok An,Sang Pyo Lee,Jeong Woong Park,Sung Hwan Jeong,Jinny Park,Eun Kyung Cho,Dong Bok Shin,Jae Hoon Lee.Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer[J].Lung Cancer.2008(1)

共引文献8

同被引文献11

引证文献1

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部